Jorge Vila

565 total citations
11 papers, 141 citations indexed

About

Jorge Vila is a scholar working on Virology, Infectious Diseases and Biochemistry. According to data from OpenAlex, Jorge Vila has authored 11 papers receiving a total of 141 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Virology, 4 papers in Infectious Diseases and 3 papers in Biochemistry. Recurrent topics in Jorge Vila's work include HIV Research and Treatment (6 papers), HIV/AIDS Research and Interventions (4 papers) and HIV/AIDS drug development and treatment (4 papers). Jorge Vila is often cited by papers focused on HIV Research and Treatment (6 papers), HIV/AIDS Research and Interventions (4 papers) and HIV/AIDS drug development and treatment (4 papers). Jorge Vila collaborates with scholars based in France, Argentina and United States. Jorge Vila's co-authors include J. Grange, Nicole Thomasset, Fabienne Nugier, F. Biron, A. Frésard, Claudine Navarro, D. Peyramond, Jean‐François Doré, Roselyne Tournaire and Brian Lockhart and has published in prestigious journals such as SHILAP Revista de lepidopterología, Brain Research and International Journal of Cancer.

In The Last Decade

Jorge Vila

9 papers receiving 131 citations

Peers

Jorge Vila

ID

VIROL

MB

BIOCH

EPIDE

Olimpia Longo Italy

Alastair Aitken United Kingdom

Jeffrey C. Umotoy United States

Hélène Jousset Sabroux Australia

Niraja Suresh United States

Karolien Stoffels Belgium

Sheila N. López Acevedo United States

Shekeba Ahmadyar United States

Montip Gettayacamin Thailand

Janine G. Borgaro United States

Olimpia Longo Italy

Jorge Vila

22 ×0.3

ID

51 ×0.8

VIROL

159 ×3.8

MB

6 ×0.3

BIOCH

25 ×1.5

EPIDE

Citations per year, relative to Jorge Vila Jorge Vila (= 1×) peers Olimpia Longo

Countries citing papers authored by Jorge Vila

Since Specialization

Citations

This map shows the geographic impact of Jorge Vila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Vila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Vila more than expected).

Fields of papers citing papers by Jorge Vila

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge Vila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Vila. The network helps show where Jorge Vila may publish in the future.

Co-authorship network of co-authors of Jorge Vila

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Vila. A scholar is included among the top collaborators of Jorge Vila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Vila. Jorge Vila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Vila, Jorge, et al.. (2023). Primary and secondary resistance of HIV-1 to integrase inhibitors in Cuban patients infected with multidrug-resistant HIV strains. SHILAP Revista de lepidopterología. 13(2). 72–72.

2.

Vila, Jorge, et al.. (2023). Tropism prediction in HIV-1 variants circulating in Cuba, 2017-2019: Implications for the pathogenesis of infection and response to Maraviroc. SHILAP Revista de lepidopterología. 13(2). 59–59.

3.

Quash, G, et al.. (2004). 4-methylthio 2-oxobutanoate transaminase: a specific target for antiproliferative agents.. PubMed. 91(4). E61–79. 6 indexed citations

4.

Vila, Jorge, et al.. (2000). Combination Therapy With Hydroxyurea Versus Without Hydroxyurea As First Line Treatment Options for Antiretroviral-Naive Patients. HIV Clinical Trials. 1(2). 1–8. 4 indexed citations

5.

Biron, F., D. Peyramond, A. Frésard, et al.. (1996). Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Research. 29(1). 111–113. 23 indexed citations

6.

Lockhart, Brian, et al.. (1995). A N-methyl-d-aspartate receptor-mediated neurotoxic effect of aspartate-based hydroxamate compounds in rat primary neuronal cultures. Brain Research. 670(2). 313–316. 6 indexed citations

7.

Biron, F., D. Peyramond, A. Frésard, et al.. (1995). Anti-HIV Activity of the Combination of Didanosine and Hydroxyurea in HIV-1-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 10(1). 36???40–36???40. 44 indexed citations

8.

Tournaire, Roselyne, et al.. (1994). Therapeutic effects of D‐aspartic acid β‐hydroxamate (DAH) on friend erythroleukemia. International Journal of Cancer. 58(3). 420–425. 15 indexed citations

9.

Lockhart, Brian, et al.. (1993). Neurotoxic effect of the anti-HIV drugd-aspartate β-hydroxamate for rat primary neuronal cultures: attenuation by N-methyl-d-aspartate (NMDA) antagonists. Brain Research. 630(1-2). 32–40. 9 indexed citations

10.

Thomasset, Nicole, Roselyne Tournaire, Claudine Navarro, et al.. (1991). Anti‐tumoral activity of L and D isomers of aspartic acid β‐hydroxamate on L5178Y leukemia. International Journal of Cancer. 49(3). 421–424. 16 indexed citations

11.

Vila, Jorge, Nicole Thomasset, Claudine Navarro, & Jean‐François Doré. (1990). In vitro and in vivo anti‐tumor activity of L‐glutamic acid γ‐monohydroxamate against L1210 leukemia and B16 melanoma. International Journal of Cancer. 45(4). 737–743. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact